Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 (Nilvanstomig) with Etoposide and Cisplatin in Advanced Neuroendocrine Carcinoma
NCT06372626Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- May 2024
- Primary completion
- Jul 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nilvanstomig in neuroendocrine carcinoma (NEC) (3 arms), sponsored by Zelgen. Primary endpoints: Dose Limiting Toxicity up to 2 years, Objective Response Rate up to 2 years and 1 more. Started May 2024; status: recruiting.
02
Drugs
nilvanstomig
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06372626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372626.